Sightera Biosciences, a Belgian
techbio company using generative AI to develop novel small-molecule therapies,
has raised €3 million in a pre-seed funding round led by Entourage, Anacura and
QBIC.
A spin-off from the University of
Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform
The funding will expand Sightera's AI-driven drug discovery platform, advance its lead oncology programme towards candidate selection, and strengthen partnerships with pharmaceutical companies.
215 words~1 min read
